GW Pharma’s latest clinical trial successful, stock soars

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price.

According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” in patients with a particular type of epilepsy during phase III clinical trials.

On Monday, after news of the trials broke, the publicly traded company’s stock shot up 16% to a record high of 811 pence on the London Stock Exchange, Reuters reported. The news agency has said the company is a possible takeover target.

The next step for GW Pharmaceuticals is approval by the U.S. Food and Drug Administration. The company plans to submit a marketing application for Epidiolex to the agency during the first half of next year.

If Epidiolex is approved, according to Reuters, it could become the first U.S.-approved drug extracted from marijuana.

GW Pharmaceuticals’ stock fell from its highs Tuesday on the Nasdaq, closing down $1.15 at $124.91.

Daily News | Briefs | Marijuana Stocks & Public Companies


  1. Aaron Birnbaum September 28, 2016
    • Lawrence Goodwin September 28, 2016
      • tom September 30, 2016
  2. Michelle DeMello September 29, 2016
    • Bob November 10, 2016
  3. Hastings RH September 29, 2016

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.